Phibro Animal Health Expands Product Offerings with New Acquisition
Phibro Animal Health Corporation (NASDAQ: PAHC) is delighted to announce a significant milestone with the completion of its acquisition of the medicated feed additive portfolio and selected water-soluble products from Zoetis Inc. (NYSE: ZTS). This strategic move is designed to enhance Phibro’s mission to promote animal health and nutrition globally.
Strategic Growth in Animal Health
With this acquisition, Phibro has effectively expanded its suite of solutions, adding a robust array of more than 37 product lines. These products will be marketed across approximately 80 countries, ensuring that the company can cater to a wide array of animal health needs. This acquisition is not just about increasing numbers; it significantly augments Phibro’s current line of offerings and reinforces its commitment to developing innovative solutions for farmers and livestock producers.
Key Benefits of The Acquisition
Jack C. Bendheim, the Chairman, President, and Chief Executive Officer of Phibro, expressed enthusiasm about this acquisition. "By incorporating these medicated feed additives into our existing portfolio, we can provide enhanced solutions tailored to cattle, swine, and poultry," he said. The integration of these products is expected to align with Phibro’s core competencies, enriching their current vaccines and nutritional specialties.
Broader Impact on Animal Health and Nutrition
This acquisition underscores Phibro’s strategy to optimize animal care standards and to prevent disease through enhanced nutrition. With six manufacturing sites located in the U.S., Italy, and China, and supported by a dedicated team of over 300 employees, the company is well-positioned to deliver its enhanced product offerings efficiently.
Financial Outlook and Future Growth
Moreover, this portfolio is anticipated to improve Phibro’s profitability and EBITDA margins, effectively becoming accretive to its Adjusted Earnings Per Share. The company plans to disclose more financial details during its upcoming first-quarter earnings call.
Commitment to Customers and Sustainability
“This is a win-win-win,” remarked Larry Miller, Phibro's Chief Operating Officer, highlighting the multifaceted benefits of this acquisition. For customers, it broadens the available solutions and expertise for global animal health needs. For consumers, it reinforces the commitment to ensuring safe and sustainable food production. And for the investors, it diversifies the company’s revenue base, enabling continued investment in new and fast-growing animal health categories.
About Phibro Animal Health Corporation
Phibro Animal Health Corporation is a well-established player in the global animal health and nutrition sector. The company aims to be a trusted partner to livestock producers, veterinarians, and consumers dedicated to the health of their animals. Phibro is committed to delivering solutions that support the overall well-being of farm and companion animals, emphasizing sustainable practices to enhance health and productivity.
Frequently Asked Questions
What recent acquisition did Phibro Animal Health Corporation complete?
Phibro Animal Health Corp completed the acquisition of Zoetis’ medicated feed additive portfolio and certain water-soluble products.
How many product lines were included in the acquisition?
The acquisition includes over 37 product lines that will be marketed in around 80 countries.
What benefits does this acquisition offer to Phibro?
This acquisition enhances Phibro’s animal health solutions, increases profitability, and expands their market reach.
Who is the CEO of Phibro Animal Health Corporation?
Jack C. Bendheim serves as the Chairman, President, and CEO of Phibro Animal Health Corporation.
What does Phibro focus on in terms of animal health?
Phibro is dedicated to optimizing global animal health and nutrition, ensuring high standards for animal care and sustainable food production.
